Evidence map›Paper›PMID 29808921›Full record

ReviewBritish journal of haematology2018

How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Christian Gisselbrecht, Eric Van Den Neste

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04024618 (A Pilot Feasibility Study of Nutritional Outcomes in Autologous Hematopoietic Stem Cell Transplant Recipients Comparing Enteral Nutrition Versus Parenteral Nutrition), which is not on this map. Cited by 94 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04024618 naunknown statusnot on this mapstarted 2019, after this paper: background citation

A Pilot Feasibility Study of Nutritional Outcomes in Autologous Hematopoietic Stem Cell Transplant Recipients Comparing Enteral Nutrition Versus Parenteral Nutrition

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2019 to 2020Enrolled40ConditionsMalignant Hematologic NeoplasmArmsParenteral Nutrition/Enteral Nutrition
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Christian GisselbrechtHôpital Saint Louis, Paris, France.ORCID 0000-0001-8079-3589
Eric Van Den NesteCliniques universitaires UCL Saint-Luc, Brussels, Belgium.
Cliniques Universitaires Saint-Luc · BEHôpital Saint-Louis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients still experience relapses. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory (R/R) DLBCL. However, half of the patients will not be eligible for transplantation due to ineffective salvage treatment, and the other half will relapse after ASCT. In randomized studies, no salvage chemotherapy regimen is superior to another. The outcomes are affected by the secondary International Prognostic Index at relapse and various biological factors. The strategy is less clear in patients who require third-line treatment. A multicohort retrospective non-Hodgkin lymphoma research (SCHOLAR-1) study conducted in 636 patients with refractory DLBCL showed an objective response rate of 26% (complete response 7%) to the next line of therapy with a median overall survival of 6·3 months. In the case of a response followed by transplantation, long-term survival can be achieved in DLBCL patients. There is clearly a need for new drugs that improve salvage efficacy. Encouraging results have been reported with chimeric antigen receptor -T cell engineering, warranting further studies in a well-defined control group of refractory patients. The Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) was used as a handy framework to build the discussion.

Indexed as

Disease ManagementAntineoplastic Combined Chemotherapy ProtocolsCell- and Tissue-Based TherapyHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseSalvage TherapyCAR-T cellscellular therapieschemotherapyHSC transplantationrefractory/relapsed DLBCL

Identifiers

PMID29808921
PMCPMC6175435
OpenAlexW2807205254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.